BTG PLC (BTG.L)

BTG.L on London Stock Exchange

654.00GBp
8:23pm IST
Change (% chg)

0.00p (+0.00%)
Prev Close
654.00p
Open
653.50p
Day's High
658.00p
Day's Low
651.00p
Volume
208,675
Avg. Vol
683,335
52-wk High
835.87p
52-wk Low
578.50p

BTG.L

Chart for BTG.L

About

BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company's Interventional Medicine segment offers a portfolio of... (more)

Overall

Beta: 0.60
Market Cap(Mil.): £2,503.61
Shares Outstanding(Mil.): 382.82
Dividend: --
Yield (%): --

Financials

  BTG.L Industry Sector
P/E (TTM): 71.19 37.25 40.68
EPS (TTM): 0.09 -- --
ROI: 4.32 16.52 15.78
ROE: 5.21 17.30 16.82
Search Stocks

Britain's BTG sees two-year build-up for varicose vein product

LONDON, May 19 - British pharmaceutical company BTG said its full-year profit was dampened by investment in new products, including its Varithena varicose veins treatment in the United States.

19 May 2015

BRIEF-BTG full-year profit dips on investments, acquisitions

* Fy pretax profit 26.7 million stg versus 33.3 million stg year ago

19 May 2015

British drugs firm BTG lifts 2014/15 sales forecast

LONDON, April 2 - British drugs company BTG nudged up its 2014/15 revenue forecast on Thursday and said it was on course for further strong growth in its new financial year.

02 Apr 2015

BRIEF-Britihs pharma co BTG launches ADR programme

* Adr programme will be open for deposits from 9 a.m. (est) today Source text for Eikon: Further company coverage:

19 Feb 2015

British drugs company BTG lifts revenue guidance

LONDON, Feb 5 - British drugs company BTG lifted its forecast for annual revenues by as much as 4 percent on Thursday, citing the benefits of a U.S. acquisition and the reversal of currency headwinds.

05 Feb 2015

BRIEF-BTG raises full-year revenue forecast

* Full year revenue is now expected to be in range 345 mln-360 mln stg; previous guidance was 330 mln-345 mln stg

05 Feb 2015

Earnings vs. Estimates

Search Stocks